Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > An elite team of influencers ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(12061)
•••
Comment by ScienceFirston May 03, 2022 7:51pm
196 Views
Post# 34653246

RE:An elite team of influencers ...

RE:An elite team of influencers ...Dr. Kamat and Dr. Peter Black will be aware of the TLD-1433 alternative.

Understanding the mechanisms driving recurrence is critical to improve outcomes for patients with NMIBC

___________________________

ScienceFirst - (5/3/2022 12:04:36 PM)
An elite team of influencers ...
One more proof:

Dr. Kamat and Dr. Peter Black:

Bladder Cancer: A practical guide



And this, April 19, 2022:

UroToday - Discussing Bladder Cancer with Harvard's Dana Farber (Dr. Alicia Morgans), MD-Anderson (Dr. Kamat) and Univ. of British-Columbia (Dr. Peter Black)


 

________________________

And just for the NMIBC indication, Roger has been able to attract top guns:

- Dr. Kamat:

... President - International Bladder Cancer Network (IBCN)
... BCAN Scientific Advisory Board
... advisor to many pharmas on NMIBC topics

- Dr. O'Donnell:

... BCAN Scientific Advisory Board
... advisor to many pharmas on NMIBC topics

- Dr. Peter Black:

... B-C University Ph. 2b site
... Chair - Medical Advisory & Research Board - Bladder Cancer Canada  
... Secretary General - International Bladder Cancer Network (IBCN))

- Dr. Kassouf :

... McGill Univ. Ph. 2b site
... Past Chair - Medical Advisory & Research Board - Bladder Cancer Canada for 10y

- Dr. Kulkarni:

... UHN. Ph. 2b site
... Ph. 2b lead investigator
... Vice-Chair - Medical Advisory & Research Board - Bladder Cancer Canada
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities